The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling

Darya Zibrova(Jena University Hospital), Regine Heller(Jena University Hospital)
Molecular and Cellular Biochemistry
July 15, 2024
Cited by 4


Related Papers